May 15, 2020: Optimized Learning While Doing: The REMAP-CAP Adaptive Platform Trial (Derek Angus, MD, MPH) - Rethinking Clinical Trials
Camrelizumab plus apatinib in patients with high-risk chemorefractory or relapsed gestational trophoblastic neoplasia (CAP 01): a single-arm, open-label, phase 2 trial - The Lancet Oncology
COVID study wins Trial of the Year award - Medicine, Nursing and Health Sciences
Seven- to eight-year follow-up of the CoolCap trial of head cooling for neonatal encephalopathy | Pediatric Research
Narrow-spectrum antibiotics for community-acquired pneumonia in Dutch adults (CAP-PACT): a cross-sectional, stepped-wedge, cluster-randomised, non-inferiority, antimicrobial stewardship intervention trial - The Lancet Infectious Diseases
Anti-Thrombotic Therapy to Ameliorate Clinical Complications in Community Acquired Pneumonia (ATTACC-CAP ) | Trial or Study
REMAP-CAP and Why we need Platform Trials in a Pandemic - YouTube
REMAP-CAP - Combacte
REMAP-CAP – The Bottom Line
The CAP-IT Trial: Amoxicillin Dose and Duration in Children with Community-Acquired Pneumonia - REBEL EM - Emergency Medicine Blog
Randomized, Embedded, Multifactorial Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP- COVID) - Sunnybrook Research Institute
Accelerating Clinical Evaluation of Repurposed Combination Therapies for COVID-19 in: The American Journal of Tropical Medicine and Hygiene Volume 103 Issue 4 (2020)
Grand Rounds August 11, 2023: The REMAP-CAP Adaptive Platform Trial: Recent Insights and Future Directions (Patrick Lawler, MD, MPH) - Rethinking Clinical Trials